



ISO International, LLC

Investment Summary

May 2017

PRIVATE AND CONFIDENTIAL

The information contained herein is not intended to be a source of advice or credit analysis with respect to the material presented, and the information and/or documents contained in this document do not constitute investment advice.

Contents

Executive Summary	3
Cannabinoid Overview	4
U.S. Regulatory Exclusions	7
International Market Opportunities	8
Core Brands and Products	9
Target Markets and Channels	22
Intellectual Property and Trademarks	23
Market Assessments	24
Financial Overview	26

Executive Summary

ISO International, LLC was established in March of 2016 by founder Jared Berry. The Company focuses on cannabinoid formulation and product development. ISO supplies a variety of medical, recreational and topical cannabinoid products to companies and end-consumers in the worldwide pharmaceutical, nutraceutical, and cosmetic markets.

Since 2009, Jared and a team of collaborators have developed proprietary cannabinoid production and purification methods while building ISODIOL, an ISO brand. ISODIOL represents a group of companies that together, grow and harvest hemp on an industrial scale, and then process it to extract the cannabinoids to the highest available purity for worldwide distribution.

The Company generated approximately \$5.90 million in sales during eight months of operations in 2016. Historical sales were driven by bulk and white label products to chemical wholesalers. The original product offering consisted of crystalline, oil/concentrate and cannaceutical products. As reflected in the Financial Overview – Forecast segment of the presentation, Company management estimates significant growth in the three years to 2020. Management expects sales to be driven by the ISODIOL, ISO Medical, and ISO Sport products.

Initial investment has allowed the Company to secure multiple distribution contracts and introduce proprietary over-the-counter (“OTC”), medical, performance and cosmetic cannabinoid solutions. ISO is exploring the use of additional capital for international sales opportunities and pharmaceutical product advancement.

Executive Management Team

- Jared Berry CEO - As a pioneer in the CBD industry in the United States, Jared has forged trails in multiple territories, establishing businesses and technologies that have set standards in the cannabis marketplace. As a pioneer in the market, Jared made CBD a viable ingredient for multiple supplements and delivery systems and as an international commodity. His innovative vision set the industry in motion and continues to move it forward as the multi-billion dollar movement into which it has evolved. Jared founded Isodiol, the industry's most innovative hemp cannabinoid product developer and manufacturer.
 - Troy Nihart COO - Troy has over 20 years of business development and entrepreneurship experience and has been an integral part of the CBD industry over the last 4 years. He has been instrumental in the development of an international supply chain for the US Market of hemp derived CBD and has developed some of the most recognized brands in the cannabis industry.
 - Dan Zuckerman Exec. Director – Dan has close to 30 years of sales experience through multiple industries. Starting in the alcohol industry, he moved up to VP Sales for a major import company. He also helped fuel the growth of Monster Energy, finishing up as the Director of Sales Military. He was in the Cannabis industry for the last three years managing the number three edible company in California.
-

Executive Management Team cont.

- **Chris Peruzzi National Sales Mngr** – Chris has 20+ years of professional experience in the Natural Products industry, concentrating in Nutraceuticals (CBD/Hemp for the past 4 years) for Manufacturer/Wholesaler, to Retail distribution. His main areas of expertise center on Sales, Marketing, Education, Product Development, Sales Management, and Key Account Management. Having held positions as National Sales Manager (Nordic Naturals, MegaFood, & Natural Balance), Director of Sales (Reserveage Organics), VP of Sales and Marketing (Symbiotics) , coupled with also owning his own Natural Products Brokerage/ Consulting firm (Rocky Mountain Naturals).
- **Ron Canfield Marketing Manager** - Ron is a marketing professional with 12+ years of multi-faceted business experience spread across automotive, consumer products, luxury goods, digital technology, and SaaS industries—from startup through Fortune 500 enterprises. In his broad background, Ron has a successful record of managing rebranding campaigns, multi-million dollar marketing budgets, developing corporate PR & social media programs, and managing eight-figure product portfolios with year-over-year growth.

Cannabinoid Overview

There are more than 100 active cannabinoids identified in cannabis.¹ Cannabinoids are chemical compounds found in cannabis or hemp plants. For the main identified cannabinoids, there have been numerous technical research studies performed.

Phytocannabinoids occur naturally in the cannabis plant. Unlike the well-known euphoric compound THC, there are other phytocannabinoids that are non-psychoactive and have widespread commercial application.

ISO is also exploring the medical benefits and commercial applications of the following cannabinoid subclasses: Cannabigerols (CBG), Cannabidivarin (CBDV) and Tetrahydrocannabivarin (THCV).




¹Borgelt LM, Franson KL, Nussbaum AM, Wang GS (February 2013). "The pharmacologic and clinical effects of medical cannabis"; Aizpurua-Olaizola, Oier; Soydaner, Umut; Öztürk, Ekin; Schibano, Daniele; Simsir, Yilmaz; Navarro, Patricia; Etxebarria, Nestor; Usobiaga, Aresatz (February 2, 2016). "Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes".

Medical Application

Cannabinoids have received extensive scientific and clinical study. Research provides a range of potentially therapeutic effects including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties.¹

The image to the right illustrates five medical categories and conditions that may potentially benefit from cannabinoid treatment.



¹National Institute on Drug Abuse: The Biology and Potential Therapeutic Effects of cannabinoid: Nora D. Volkow, Director, National Institute on Drug Abuse Senate Caucus on International Narcotics Control

²Image sourced from Leafly: a cannabis news and information repository

Procurement & Formulation

ISO maintains exclusive access to large-scale industrial hemp production. The Company leverages these relationships and proprietary processing technology to obtain the purest cannabinoids in the market. The extracted cannabinoids can be delivered as a raw material or formulated into oil and other proprietary products.

There are two primary approaches to cannabinoid procurement. These include industrial plant breeding/harvesting programs (“industrial hemp cultivation”) and artificial manufacturing methods (“synthetic cannabinoid”).

Industrial hemp cultivation provides cost and cannabinoid formulation advantages to alternative methods. Our proprietary purification processes are ISO 9001 certified and GMP certified. These international certifications are extremely difficult to obtain and reflect industry-best standards.




U.S. Regulatory Exclusions¹

Cannabinoids can be made from the mature stalks of the industrial hemp plants and can be legally imported into the United States under Federal Law. This allows consumers to get the cannabinoid treatments they need without fear of violating any Federal Laws.

According to the Hoban Law Group (“HLG”), cannabinoids are not illegal if they are derived from certain parts of the hemp plant, such as mature stalks. The following is a discussion of prior litigation and conclusions regarding cannabinoids published by HLG:

By definition, the listing of "marihuana" in Schedule I excludes the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination... Thus, any extracts derived from the foregoing portions of a Cannabis sativa L plant lawfully cultivated outside of the United States remain lawful.

Marijuana Legalization by State²




Recreational Marijuana	Medical Marijuana	Limited Medical Marijuana*
Alaska California Colorado Massachusetts Nevada Oregon Washington Washington, D.C.	Arizona Arkansas Connecticut Delaware Florida Hawaii Illinois Maine Maryland Michigan Minnesota	Alabama Georgia Iowa Kentucky Louisiana Mississippi Missouri North Carolina South Carolina Tennessee

* Limited medical marijuana includes cannabis extracts that are high in cannabidiol and low in tetrahydrocannabinol.

¹HLG Response to DEA Federal Register – December 14, 2016.

²Reflects State Legislature as of November, 2016 – A 2016 Purch and Livescience.com illustration

International Market Opportunities



Core Brands & Products

ISO is a world leader in the sale of cannabinoid crystalline and manufactures more than 25 cannabinoid-infused products. The Company also maintains exclusive agreements to supply cannabinoid solutions to product manufacturers such as CBDNaturals. CBDNaturals, a related party, is a distributor and supplier of nano-amplified cannabinoid bottled water and enhanced beverage products. The company is engaged in the marketing and sale of water which contains anti-oxidants, vitamins and minerals that improves the immune system. ISO supplies all of the nano-amplified, NanoUltra and Heneplex products used by CBDNaturals.

The following represent historically high-volume ISO products:



ISO's extended/sample product offering is provided on the following pages.

ISODIOL – Primary Product Offering



ISODIOL – Primary Product Offering



ISO Medical – Sample Product Offering




Other ISO Brand Products




ISO Sport – Sample Product Offering



ISO Brand Family Waters



CBDNaturals Brand Products



CBDNaturals Brand Products




CBD Xtreme Brand Products




CBD Xtreme Brand Products



CBD Xtreme Brand Products



Brand Segments – Overview



Target Markets and Channels

Chemical Distributors/Wholesalers

- ISO targets Chemical Wholesalers who distribute primarily to R&D clinics studying cannabinoid for potential therapeutic applications.

Retail/Online Sales

- The Company has established an online portal for web-based sales. This enables researchers and other qualified parties to order online in small quantities (milligrams and grams) at higher price points than larger quantity distribution channels.

Pharmaceuticals

- ISO supplies cannabinoid products to pharmaceutical companies in the process of research, clinical trials, and/or product roll-out.

Nutraceuticals

- ISO supplies nutraceutical companies with cannabinoids for a variety of consumer products. Companies market cannabinoid products as natural remedies for pain and inflammation, as well as enhancement of mood and mental focus. Products may include natural supplements, gum, mints, nutrition bars, and energy drinks.

Cosmetics

- Cosmetic, health and beauty-care companies use cannabinoids to enhance their anti-aging, skin damage repair, and personal beauty product offerings.

Intellectual Property & Trademarks¹

Pending Trademarks

*Owned by ISO International,
LLC:*

- ANTIDOPE
- ANTIDOPE
- CBD 7
- CBD Spheres
- CBDNANOMIST
- CHRONIC CREAM
- CHRONIC SPRAYS
- CANATRU
- CEBATRU
- CBD Xtreme
- ISOSPORT
- CHRONIC GUMMIES
- CHRONIC WATER

Pending Trademarks

*“USE” Trademarks to be assigned
to ISO International, LLC:*

- CMD
- CEBIDIOL
- HENEPLEX
- ISODIOL
- NANOBUHA
- RAPID CBD
- THC FREE & Design


“USE” presumes the USPTO’s acceptance of the filed Statement of Use for trademark usage.

¹Reflects information provided by Management.

Hemp-Based Cannabinoid Market Assessment

According to the Hemp Business Journal (HBJ), in 2015 the U.S. generated \$90 million in hemp-based cannabinoid product sales across seven distinct channels. Internet/Other Direct and Smoke Shops accounted for approximately 85% of product sales. Existing sales channels are expected to continue maturing and adapting along with the formalizing regulatory environment and medical applications of cannabinoids in the three years to 2020.

\$90 Million U.S. Hemp Based CBD Product Sales by Channel in 2015




Source: Hemp Business Journal estimates (consumer sales)

HempBusinessJournal

Hemp-Based Cannabinoid Market Assessment

HBJ forecasts the entire U.S. cannabinoid market will increase to \$2.1 billion by 2020 and that \$450 million of those sales will be from hemp-based sources, and the rest from marijuana sources.¹ Pharmaceuticals and internet retail channels are expected to drive sales collectively accounting for 62% of total sales, or approximately \$279.0 million.

\$450 Million U.S. Hemp-Based CBD Product Sales by Channel in 2020e



Source: Hemp Business Journal estimates (consumer sales)

HempBusinessJournal

¹The cannabinoid Report 2016-2020: Hemp Business Journal; cannabinoid

Financial Overview – Historical¹

ISO International, LLC				
Historical Profit and Loss Statement ¹				
<i>Actual \$ Figures</i>	Q2	Q3	Q4	Total 2016²
Sales (by Channel):				
MMJ - REC	\$0	\$2,440	\$45,502	\$47,942
Vape - Smoke	0	0	4,025	4,025
C-Store - IHFS	2,149	238,712	937	241,798
Chain National Stores	44,326	60,975	111,482	216,783
White Label	29,580	15,006	61,976	106,562
Medical	0	7,300	26,785	34,085
Cosmetics - Spa	0	91,080	282,481	373,561
Bulk	785,654	1,264,036	2,860,130	4,909,821
Total Sales	\$861,710	\$1,679,549	\$3,393,319	\$5,934,578
Shipping and Freight	5,289	19,789	27,846	52,924
Total Income	\$866,999	\$1,699,338	\$3,421,166	\$5,987,502
Total Cost of Goods Sold	(481,191)	(1,037,761)	(1,940,741)	(3,459,694)
Gross Profit	\$385,807	\$661,577	\$1,480,424	\$2,527,808
<i>% Margin</i>	<i>44.8%</i>	<i>39.4%</i>	<i>43.6%</i>	<i>42.6%</i>
Total Operating Expenses	(178,298)	(600,810)	(891,693)	(1,670,801)
Net Other Income	0	0	(6,528)	(6,528)
Net Income	\$207,509	\$60,766	\$582,203	\$850,478
<i>% Margin</i>	<i>24.1%</i>	<i>3.6%</i>	<i>17.2%</i>	<i>14.3%</i>

¹Represents trailing 8-months of operations. Income taxes are not reflected.

²Reflects total for period May 1, 2016 to December 31, 2016.



¹Reflects actual results from eight months of operations, updated by Management as of March 15, 2017.

Financial Overview – Historical Sales¹

2016 Monthly Sales by Brand Category

Number of Identified Brand Categories: 8

<i>Actual \$ figures</i>										
<u>Brand Category</u>	<u>May</u>	<u>June</u>	<u>July</u>	<u>Aug.</u>	<u>Sept.</u>	<u>Oct.</u>	<u>Nov.</u>	<u>Dec.</u>	<u>8-Month Total</u>	<u>% of Total</u>
Isodiol	\$33,594	\$752,060	\$253,801	\$278,610	\$720,467	\$731,101	\$845,257	\$955,430	\$4,570,320	80.7%
TruSpectrum	0	0	0	1,000	90,080	95,330	82,928	106,023	375,361	6.6%
Cannaceuticals	0	2,149	235	237,180	1,297	0	0	3,792	244,653	4.3%
White Label	0	29,580	0	0	9,850	61,150	130,751	0	231,331	4.1%
CBDNaturals	141	2,360	11,413	14,559	35,004	16,589	18,219	13,674	111,958	2.0%
Iso Medical	0	0	454	6,079	14,320	13,854	14,378	27,457	76,541	1.4%
Unidentified	0	51,825	0	0	0	800	750	0	53,375	0.9%
CBD Xtreme	0	0	0	24	0	130	0	3,058	3,213	0.1%
Total	\$33,735	\$837,974	\$265,903	\$537,451	\$871,017	\$918,954	\$1,092,283	\$1,109,434	\$5,666,752	100.0%

ISO International’s historical sales are composed of 8 different product brands, including ISODIOL, CBDNaturals and ISO Medical. ISODIOL sales are generated by bulk products including proprietary cannabinoid crystalline and oils/concentrates. ISODIOL products accounted for approximately 80.0% of 2016 sales. The Company has identified and positioned the ISODIOL, ISO Medical, Cannaceuticals, and newly released ISO Sport brands for significant growth in the three years to 2020.

¹Reflects trailing 8-month 2016 total sales from Company invoice data as of March 3, 2017.

Financial Overview – Historical Sales¹

2016 Monthly Sales by Product Type

Number of Identified Product Types: 7

<i>Actual \$ figures</i>										
<u>Product Category</u>	<u>May</u>	<u>June</u>	<u>July</u>	<u>Aug.</u>	<u>Sept.</u>	<u>Oct.</u>	<u>Nov.</u>	<u>Dec.</u>	<u>8-Month Total</u>	<u>% of Total</u>
Crystalline	\$31,997	\$719,063	\$228,743	\$246,694	\$685,471	\$660,076	\$754,340	\$849,556	\$4,175,940	73.7%
Oils / Concentrates	1,597	32,998	25,058	32,741	124,677	164,808	153,236	200,644	735,760	13.0%
Topicals	0	31,729	690	240,432	5,435	68,484	38,089	20,199	405,058	7.1%
Beverage Related	141	2,360	9,038	6,226	38,267	8,352	80,181	11,345	155,909	2.8%
Sprays - Aerosol	0	0	0	2,973	10,579	8,362	42,680	13,880	78,476	1.4%
Edibles / Supplements	0	0	2,375	8,385	6,587	8,872	23,005	13,810	63,034	1.1%
Other	0	51,825	0	0	0	0	750	0	52,575	0.9%
Total	\$33,735	\$837,974	\$265,903	\$537,451	\$871,017	\$918,954	\$1,092,283	\$1,109,434	\$5,666,752	100.0%

The Company segments historical sales into 7 product types, or categories. Crystalline and Oils/Concentrate products, represented by the ISODIOL and White Label brands, generated approximately 87% of sales over the trailing 8-month period. These products are primarily sold via bulk wholesale channels. ISO forecasts significant growth in Topical products sales as a result of multi-year distribution contracts associated with the Cannaceuticals, White Label and ISO Medical brands.

¹Reflects trailing 8-month 2016 total sales from Company invoice data as of March 3, 2017.

Distribution Agreement Structure

Company projections include both direct sales and licensing agreements with milestone provisions. Licensing revenues are derived from contracting with select parties to enter into exclusive distribution agreements with ISODIOL for certain product types in specific geographic regions. These licensing agreements entail payment of an upfront fee for exclusive rights, and additional payments based on the achievement of sales quantity milestones. The table below outlines a proposed agreement structure and base case revenues:

ISO International, LLC	
Distribution Agreement - Proposed Structure ¹	
Agreement Conditions:	
¹ Supplier (ISO International) grants Distributor exclusive, non-sublicenseable, license and right to market, promote and distribute specific products to customers (i.e. cannaceutical products).	
² Non-Competition clause for specific products during the agreement.	
⁴ During the first two years of the Initial Term, distributor shall order a minimum of \$1,500,000 of Product from the supplier at wholesale pricing.	
⁵ Provided that the minimum order is achieved during the initial term, the agreement shall renew for an additional 3 years provided that the minimum order to be placed by distributor follows the a step-up schedule: \$3,000,000 in year three; \$4,000,000 in year four; \$5,000,000 in year five.	
⁶ Renewal term is subject to the Supplier receiving an additional \$100,000 (negotiable via issuance of shares of common stock in the distributor)	
Projected Revenues per 2-year Agreement - Base Case:	
Notes:	Amount
One-time license fee paid to Supplier (negotiable via issuance of shares of common stock in the distributor)	\$100,000
Numer of Product (units) ordered	81,081 units
Pricing for products neegotiated with Distributor	\$18.50
Total Purchases	\$1,500,00
Total Revenues - Base Case	\$1,600,000
¹ Reflects example distribution agreement structure.	
² Pulled from wholesale white label product pricing. Units were calculated based on wholesale price and minimum 2-year contract	



Projections Disclaimer

"The financial projections are preliminary and subject to change; the Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, and unanticipated events and circumstances may affect the ultimate financial results. Projections are inherently subject to substantial and numerous uncertainties and to a wide variety of significant business, economic and competitive risks, and the assumptions underlying the projections may be inaccurate in any material respect. Therefore, the actual results achieved may vary significantly from the forecasts, and the variations may be material."

Financial Overview – Forecast

ISO International, LLC

Projected Profit and Loss Statement¹

Figures in \$000's

YEAR	Projection Period								
	2017	2018	2019	2020	2021	2022	2023	2024	2025
Total Income²	\$23,226	\$39,086	\$60,058	\$77,406	\$88,261	\$96,336	\$101,984	\$106,119	\$109,199
Revenue Growth %	287.7%	68.3%	53.7%	28.9%	14.0%	9.1%	5.9%	4.1%	2.9%
Total Cost of Goods Sold	(12,963)	(17,439)	(23,821)	(30,702)	(35,007)	(38,210)	(40,450)	(42,090)	(43,311)
Gross Profit	\$10,263	\$21,647	\$36,237	\$46,705	\$53,254	\$58,127	\$61,534	\$64,029	\$65,887
Gross Profit Margin %	44.6%	55.9%	60.9%	60.9%	60.9%	60.9%	60.9%	60.9%	60.9%
Total Operating Expenses ³	(6,507)	(12,228)	(19,979)	(25,750)	(29,361)	(32,047)	(33,926)	(35,302)	(36,326)
Net Income	\$3,756	\$9,419	\$16,258	\$20,955	\$23,893	\$26,079	\$27,608	\$28,727	\$29,561
Net Income Margin %	16.3%	24.3%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%
EBITDA	\$3,756	\$9,419	\$16,258	\$20,955	\$23,893	\$26,079	\$27,608	\$28,727	\$29,561
EBITDA Margin %	16.3%	24.3%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%	27.3%

¹Reflects projections provided by Company Management.

²Calculated as total sales net of shipping and freight income.

³Management indicates that 20% of total operating costs, which will be allocated to partial ownership in Carlsbad Naturals, LLC.

